{
    "info": {
        "Nasdaq_Traded": "Y",
        "Symbol": "ARDS",
        "Security_Name": "Aridis Pharmaceuticals Inc. - Common Stock",
        "Listing_Exchange": "Q",
        "Market_Category": "S",
        "ETF": "N",
        "Round_Lot_Size": "100.0",
        "Test_Issue": "N",
        "Financial_Status": "N",
        "CQS_Symbol": "",
        "NASDAQ_Symbol": "ARDS",
        "NextShares": "N"
    },
    "history": [],
    "recommendationTrend": {
        "trend": [
            {
                "period": "0m",
                "strongBuy": 0,
                "buy": 3,
                "hold": 0,
                "sell": 0,
                "strongSell": 0
            },
            {
                "period": "-1m",
                "strongBuy": 0,
                "buy": 2,
                "hold": 1,
                "sell": 0,
                "strongSell": 0
            },
            {
                "period": "-2m",
                "strongBuy": 0,
                "buy": 2,
                "hold": 1,
                "sell": 0,
                "strongSell": 0
            },
            {
                "period": "-3m",
                "strongBuy": 0,
                "buy": 0,
                "hold": 0,
                "sell": 0,
                "strongSell": 0
            }
        ],
        "maxAge": 86400
    },
    "summaryDetail": {
        "maxAge": 1,
        "priceHint": 4,
        "previousClose": 1.41,
        "open": 1.46,
        "dayLow": 1.26,
        "dayHigh": 1.4769,
        "regularMarketPreviousClose": 1.41,
        "regularMarketOpen": 1.46,
        "regularMarketDayLow": 1.26,
        "regularMarketDayHigh": 1.4769,
        "payoutRatio": 0,
        "beta": 1.39659,
        "forwardPE": -1.6117647,
        "volume": 126417,
        "regularMarketVolume": 126417,
        "averageVolume": 99420,
        "averageVolume10days": 184290,
        "averageDailyVolume10Day": 184290,
        "bid": 1.29,
        "ask": 1.38,
        "bidSize": 800,
        "askSize": 900,
        "marketCap": 19253980,
        "fiftyTwoWeekLow": 0.68,
        "fiftyTwoWeekHigh": 2.94,
        "priceToSalesTrailing12Months": 6.4588995,
        "fiftyDayAverage": 0.9874,
        "twoHundredDayAverage": 1.277,
        "currency": "USD",
        "fromCurrency": null,
        "lastMarket": null,
        "algorithm": null,
        "tradeable": false
    },
    "earnings": {
        "maxAge": 86400,
        "earningsChart": {
            "quarterly": [
                {
                    "date": "3Q2021",
                    "actual": -1.94,
                    "estimate": -0.51
                },
                {
                    "date": "4Q2021",
                    "actual": -0.92,
                    "estimate": -0.41
                },
                {
                    "date": "1Q2022",
                    "actual": -0.44,
                    "estimate": -0.51
                },
                {
                    "date": "2Q2022",
                    "actual": -0.45,
                    "estimate": -0.06
                }
            ],
            "currentQuarterEstimate": -0.17,
            "currentQuarterEstimateDate": "3Q",
            "currentQuarterEstimateYear": 2022,
            "earningsDate": [
                1680048000,
                1680480000
            ]
        },
        "financialsChart": {
            "yearly": [
                {
                    "date": 2018,
                    "revenue": 2757000,
                    "earnings": -22105000
                },
                {
                    "date": 2019,
                    "revenue": 1022000,
                    "earnings": -29681000
                },
                {
                    "date": 2020,
                    "revenue": 1000000,
                    "earnings": -22333000
                },
                {
                    "date": 2021,
                    "revenue": 1535000,
                    "earnings": -42193000
                }
            ],
            "quarterly": [
                {
                    "date": "3Q2021",
                    "revenue": 515000,
                    "earnings": -21002000
                },
                {
                    "date": "4Q2021",
                    "revenue": 987000,
                    "earnings": -8810000
                },
                {
                    "date": "1Q2022",
                    "revenue": 1187000,
                    "earnings": -7766000
                },
                {
                    "date": "2Q2022",
                    "revenue": 292000,
                    "earnings": -7979000
                }
            ]
        },
        "financialCurrency": "USD"
    },
    "calendarEvents": {
        "maxAge": 1,
        "earnings": {
            "earningsDate": [
                1680048000,
                1680480000
            ],
            "earningsAverage": -0.17,
            "earningsLow": -0.49,
            "earningsHigh": 0.45,
            "revenueAverage": 7470000,
            "revenueHigh": 22100000
        }
    },
    "upgradeDowngradeHistory": {
        "history": [
            {
                "epochGradeDate": "2022-08-16T00:00:00.000Z",
                "firm": "Maxim Group",
                "toGrade": "Hold",
                "fromGrade": "Buy",
                "action": "down"
            },
            {
                "epochGradeDate": "2021-07-20T00:00:00.000Z",
                "firm": "HC Wainwright & Co.",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "main"
            },
            {
                "epochGradeDate": "2020-05-15T00:00:00.000Z",
                "firm": "HC Wainwright & Co.",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "reit"
            },
            {
                "epochGradeDate": "2020-02-19T00:00:00.000Z",
                "firm": "Roth Capital",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "init"
            },
            {
                "epochGradeDate": "2019-12-30T00:00:00.000Z",
                "firm": "HC Wainwright & Co.",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "init"
            },
            {
                "epochGradeDate": "2018-09-10T00:00:00.000Z",
                "firm": "Cantor Fitzgerald",
                "toGrade": "Overweight",
                "fromGrade": "",
                "action": "init"
            },
            {
                "epochGradeDate": "2018-09-10T00:00:00.000Z",
                "firm": "Laidlaw & Co.",
                "toGrade": "Buy",
                "fromGrade": "",
                "action": "init"
            },
            {
                "epochGradeDate": "2018-09-10T00:00:00.000Z",
                "firm": "Northcoast Research",
                "toGrade": "Outperform",
                "fromGrade": "",
                "action": "init"
            }
        ],
        "maxAge": 86400
    },
    "price": {
        "maxAge": 1,
        "preMarketSource": "DELAYED",
        "postMarketChangePercent": 0,
        "postMarketChange": 0,
        "postMarketTime": "2023-01-07T00:20:37.000Z",
        "postMarketPrice": 1.37,
        "postMarketSource": "DELAYED",
        "regularMarketChangePercent": -0.028368765,
        "regularMarketChange": -0.03999996,
        "regularMarketTime": "2023-01-06T21:00:04.000Z",
        "priceHint": 4,
        "regularMarketPrice": 1.37,
        "regularMarketDayHigh": 1.4769,
        "regularMarketDayLow": 1.26,
        "regularMarketVolume": 126417,
        "averageDailyVolume10Day": 184290,
        "averageDailyVolume3Month": 99420,
        "regularMarketPreviousClose": 1.41,
        "regularMarketSource": "FREE_REALTIME",
        "regularMarketOpen": 1.46,
        "exchange": "NCM",
        "exchangeName": "NasdaqCM",
        "exchangeDataDelayedBy": 0,
        "marketState": "CLOSED",
        "quoteType": "EQUITY",
        "symbol": "ARDS",
        "underlyingSymbol": null,
        "shortName": "Aridis Pharmaceuticals Inc.",
        "longName": "Aridis Pharmaceuticals, Inc.",
        "currency": "USD",
        "quoteSourceName": "Delayed Quote",
        "currencySymbol": "$",
        "fromCurrency": null,
        "lastMarket": null,
        "marketCap": 19253980
    },
    "defaultKeyStatistics": {
        "maxAge": 1,
        "priceHint": 4,
        "enterpriseValue": 24319096,
        "forwardPE": -1.5568182,
        "profitMargins": 0,
        "floatShares": 13837866,
        "sharesOutstanding": 14054000,
        "sharesShort": 208988,
        "sharesShortPriorMonth": 125739,
        "sharesShortPreviousMonthDate": 1663200000,
        "dateShortInterest": 1665705600,
        "sharesPercentSharesOut": 0.0117999995,
        "heldPercentInsiders": 0.12877,
        "heldPercentInstitutions": 0.08073,
        "shortRatio": 0.69,
        "shortPercentOfFloat": 0.0128999995,
        "beta": 1.39659,
        "category": null,
        "bookValue": -0.862,
        "fundFamily": null,
        "legalType": null,
        "lastFiscalYearEnd": "2021-12-31T00:00:00.000Z",
        "nextFiscalYearEnd": "2023-12-31T00:00:00.000Z",
        "mostRecentQuarter": "2022-06-30T00:00:00.000Z",
        "netIncomeToCommon": -48698000,
        "trailingEps": -2.436,
        "forwardEps": -0.85,
        "pegRatio": -0.02,
        "lastSplitFactor": null,
        "enterpriseToRevenue": 8.158,
        "enterpriseToEbitda": -0.55
    },
    "summaryProfile": {
        "address1": "983 University Avenue",
        "address2": "Building B",
        "city": "Los Gatos",
        "state": "CA",
        "zip": "95032",
        "country": "United States",
        "phone": "408 385 1742",
        "fax": "408 356 9548",
        "website": "https://www.aridispharma.com",
        "industry": "Biotechnology",
        "sector": "Healthcare",
        "longBusinessSummary": "Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.",
        "fullTimeEmployees": 34,
        "companyOfficers": [],
        "maxAge": 86400
    },
    "financialData": {
        "maxAge": 86400,
        "currentPrice": 1.37,
        "targetHighPrice": 19,
        "targetLowPrice": 5,
        "targetMeanPrice": 12,
        "targetMedianPrice": 12,
        "recommendationMean": 2.3,
        "recommendationKey": "buy",
        "numberOfAnalystOpinions": 2,
        "totalCash": 6317000,
        "totalCashPerShare": 0.357,
        "ebitda": -44226000,
        "totalDebt": 13000000,
        "quickRatio": 0.252,
        "currentRatio": 0.412,
        "totalRevenue": 2981000,
        "revenuePerShare": 0.189,
        "returnOnAssets": -1.99208,
        "grossProfits": -35401000,
        "freeCashflow": -19551624,
        "operatingCashflow": -28627000,
        "revenueGrowth": 7.848,
        "grossMargins": 0,
        "ebitdaMargins": 0,
        "operatingMargins": -15.008051,
        "profitMargins": 0,
        "financialCurrency": "USD"
    }
}